
Tenaya Therapeutic (TNYA) Stock Forecast & Price Target
Tenaya Therapeutic (TNYA) Analyst Ratings
Bulls say
Tenaya Therapeutics is well positioned for long-term success, with a strong pipeline and a sound financial position, evident from the recent positive results from its clinical trials and the successful public offering in December 2025. There are potential manufacturing constraints and regulatory risks, but the company's promising partnerships with the likes of Alnylam Pharmaceuticals and successful resolution of a FDA clinical hold show its resilience in overcoming obstacles and driving its innovative platform forward. The dynamic and competitive nature of the gene therapy market adds uncertainty, but Tenaya's established presence in the realm of heart disease treatments and continued advancements in its platforms make it a promising investment opportunity.
Bears say
Tenaya Therapeutics is a clinical-stage biotechnology company that is working on therapies for rare genetic disorders and heart conditions, with a specific focus on cellular regeneration, gene therapy, and precision medicine. Despite promising initial clinical data from their programs, comparisons between other companies in the sector and lack of clear superiority make it difficult to determine the potential success of Tenaya's products. Additionally, there are risks associated with the manufacturing and commercialization of AAV-based gene therapy products, which could impact the company's potential success.
This aggregate rating is based on analysts' research of Tenaya Therapeutic and is not a guaranteed prediction by Public.com or investment advice.
Tenaya Therapeutic (TNYA) Analyst Forecast & Price Prediction
Start investing in Tenaya Therapeutic (TNYA)
Order type
Buy in
Order amount
Est. shares
0 shares